We entered the global market with the hepatitis B vaccine `HEPACCINE-B` developed by using only locally developed technology.
Entering the fluids business
We greatly improved the treatment environment by launching safe-flex IV solutions (bag fluids) for the first time in Korea.
'CONDITION' opened the anti-hangover drinks market for the first time in Korea.
CONDITION has held the title of No.1 anti-hangover drink in the market for 25 years since its first introduction in Korea. It is spreading a new hangover-easing culture beyond Korea in China, Vietnam and Japan.
Development of the EPO formulation 'EPOKINE' for the first time in Korea and the third time in the world
CJ HealthCare Corp. is leading the localization of drugs through continuous R&D.
Launching the fixed dose combination IMD for hypertension 'EXONE'
EXONE is the fixed dose combination IMD for hypertension applied with amlodipine adipate developed by CJ HealthCare Corp.
Launching the fixed dose combination IMD for hypertension 'MACHKHAN'
CJ HealthCare Corp. is improving the quality of patients' lives by launching MACHKHAN, a combination of candesartan and amlodipine, for the first time in Korea.